We claim:

1. A combination of, a) a compound of formula I:



(I)

or a pharmaceutically acceptable salt thereof; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib, or a pharmaceutically acceptable salt thereof, for the prophylactic or therapeutic treatment of a hyperproliferative disorder.

2. The combination of claim 1 wherein the hyperproliferative disorder is cancer.

3. The combination of claim 2 wherein the cancer is associated with PTEN mutation.

4. The combination of claim 2 wherein the cancer is associated with AKT mutation, overexpression or amplification.

5. The combination of claim 2 wherein the cancer is associated with PI3K mutation.

6. The combination of claim 2 wherein the cancer is associated with Her2/ErbB2 mutation or amplification.

7. The combination of any one of claims 2-6 wherein cancer is selected from, breast, lung, ovarian, prostate, melanoma, gastric, colon, renal, head and neck, and giloma.

8. The combination of any one of claims 2-6 wherein the compound of formula I or the pharmaceutically acceptable salt thereof and 5-FU are to be administered to the mammal.

9. The combination of claim 8 wherein the cancer is breast cancer.

10. The combination of claim 8 wherein further comprising ~~administering~~ administration of oxaliplatin to the mammal.

11. The combination of claim 10 further comprising ~~administering~~ administration of folinic acid to the mammal.

12. The combination of claim 10 or 11 wherein the cancer is gastric, ovarian, or colon.

13. The combination of any one of claims 2-6 wherein the compound of formula I or the pharmaceutically acceptable salt thereof and carboplatin are to be administered to the mammal.

14. The combination of claim 13 wherein the cancer is breast, lung, or prostate.

15. The combination of any one of claims 2-6 wherein the compound of formula I or the pharmaceutically acceptable salt thereof and irinotecan are to be administered to the mammal.

16. The combination of claim 15 wherein the cancer is colon.

17. The combination of any one of claims 2-6 wherein the compound of formula I or the pharmaceutically acceptable salt thereof and docetaxel are to be administered to the mammal.

18. The combination of claim 17 wherein the cancer is breast, giloma, lung, melanoma, ovarian, or prostate.

19. The combination of claim 17 wherein the cancer is breast, ovarian, or prostate.

20. The combination of any one of claims 2-6 wherein the compound of formula I or the pharmaceutically acceptable salt thereof and doxorubicin are to be administered to the mammal.

21. The combination of claim 20 wherein the cancer is breast, lung, ovarian, giloma, or prostate.

22. The combination of any one of claims 2-6 wherein the compound of formula I or the pharmaceutically acceptable salt thereof and SN-38 are to be administered to the mammal.

23. The combination of claim 22 wherein the cancer is colon.

24. The combination of any one of claims 2-6 wherein the compound of formula I or the pharmaceutically acceptable salt thereof and temozolomide are to be administered to the mammal.

25. The combination of claim 24 wherein the cancer is giloma.

26. The combination of any one of claims 2-6 wherein the compound of formula I or the pharmaceutically acceptable salt thereof and a platinum agent are to be administered to the mammal.

27. The combination of claim 26 wherein the cancer is ovarian.

28. The combination of any one of claims 2-6 wherein temozolomide is to be administered.

29. The combination of any one of claims 2-6 wherein bevacizumab is to be administered.

30. The combination of any one of claims 1-29 wherein the combination provides a synergistic effect in treating the hyperproliferative disorder.

31. The combination of claim 30 wherein Combination Index value of the synergistic effect is less than about 0.8.

32. A compound of formula Ia or a pharmaceutically acceptable salt thereof, as defined in claim 1 for therapeutic use for improving the quality of life of a patient treated for a hyperproliferative disorder with an agent selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib.

33. Use of a) a compound of formula I or a pharmaceutically acceptable salt thereof; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib in the manufacture of a medicament ~~A method~~ for treating a disease or condition modulated by AKT kinase in a mammal. ~~comprising, administering to the mammal, a) a compound of formula I or a pharmaceutically~~

~~acceptable salt thereof; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib.~~

34. ~~A method for treating a hyperproliferative disorder in a mammal comprising, administering to the mammal~~Use of a combination of, a) a compound of formula I:



(I)

or a pharmaceutically acceptable salt thereof; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib in the manufacture of a medicament for treating a hyperproliferative disorder in a mammal.

35. The combination of a) a compound of formula I or a pharmaceutically acceptable salt thereof; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib.

36. The use of a compound of formula I or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of a hyperproliferative disorder in a mammal, wherein one or more agents selected 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib are to be administered to the mammal.

37. The use of a compound of formula I or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of a disease or condition modulated by AKT kinase in a mammal, wherein one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine,

temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib are to be administered to the mammal.

38. A kit comprising a compound of formula I or a pharmaceutically acceptable salt thereof, a container, and a package insert or label indicating the administration of the compound of formula I with one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib for treating a hyperproliferative disorder.

39. A system comprising a compound having formula I or a pharmaceutically acceptable salt thereof, and a chemotherapeutic agent selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib; as a combined preparation for separate, simultaneous or sequential use in the treatment of a hyperproliferative disorder.